{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "OFIX",
  "name": "Orthofix Medical Inc.",
  "url": "https://frontierpicks.com/dossiers/OFIX/",
  "json_url": "https://frontierpicks.com/dossiers/OFIX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "The CMS-reversal re-rate has fully round-tripped: after the 2026-07-02 rate restoration and a 2026-08-05 beat-and-raise, OFIX closed $10.01 on 2026-08-21 — below where it traded on the 2026-05-21 guidance-cut 8-K — with RSI(14) at 22.8 and two sell-side targets cut to $13. The narrative's own catalysts fired and paid nothing; nothing dated until the ~November Q3 print.",
  "invalidation_trigger": "A weekly close below $9.80 loses the $10 handle intact at the 2026-08-21 close of $10.01 and completes the retrace of the July CMS-reversal advance; secondary, a ~2026-11-04 Q3 print with adjusted EBITDA below the year-ago $20.6M and free cash flow still negative on top of $(47.1)M for the six months.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "small-cap-value-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Medicare rates on HCPCS E0747/E0748/E0760 set a material share of Therapeutic Solutions revenue and can change at CMS discretion; the 2026-05-18 cut took effect with days of notice.",
    "The 2026-05-21 8-K stated the company does not expect positive free cash flow for full-year 2026; six-month FCF was $(47.1)M.",
    "Three-year targets withdrawn 2026-05-21 remain withdrawn, and management said on 2026-08-12 it will not give 2027 guidance until the U.S. spine business stabilises.",
    "Balance sheet at Q2 2026: cash and equivalents $103.8M against $221.6M long-term debt, against a loss-making quarterly run-rate.",
    "FDA moved non-invasive bone growth stimulators from Class III to Class II on 2026-04-16, lowering the entry barrier for 510(k) competitors in the franchise."
  ],
  "body_markdown": "## Current Thesis\nThe leg on offer in July was a reimbursement-reversal re-rate, and it has now been given back in full. CMS restored the pre-2026-05-18 Medicare rates on non-invasive bone growth stimulators (HCPCS E0747/E0748/E0760), reported 2026-07-02; the 2026-08-05 Q2 print then cleared consensus on both lines and carried an FY26 guidance raise to $845–855M of net sales and $95–98M of adjusted EBITDA. The tape treated the confirming event as an exit. Seeking Alpha put the print-day reaction near -10% (2026-08-06), the shares closed $10.28 on 2026-08-07 and $10.01 on 2026-08-21 — 38.3% below the $16.23 52-week high, with RSI(14) at 22.8. A three-month price change of -6.9% puts the last close under the level of 2026-05-21, the day the guidance-cut 8-K landed. What the reversal was supposed to pay for has been unwound, and the next dated company event is the Q3 print in early November.\n\n## Bull Case\n- CMS restoration is in force rather than pending: pre-May-18 rates restored per the company statement reported 2026-07-02, reversing the ~10% average cut the 2026-05-21 8-K identified as the reason guidance was pulled down.\n- FY26 guidance moved up on both lines on 2026-08-05 — net sales to $845–855M from $838–848M, adjusted EBITDA to $95–98M from $90–93M, framed by the company as roughly 80bps of margin expansion versus 2025.\n- Q2 2026 beat: net sales $210.933M against a $209.277M consensus, adjusted EPS $0.07 against a $(0.41) estimate, reported sales +4% YoY and ~5% pro forma constant currency.\n- Concentration is working where the revenue actually sits: at Canaccord Genuity's 46th Annual Growth Conference on 2026-08-12, management said ~80% of spine revenue comes from the top 40 distributors and that cohort is growing above market.\n- CFO Julie Andrews gave the first quantified Q3 shape since the print on 2026-08-12 — Q3 revenue expected roughly level with Q2, and \"a little bit of expansion versus prior year EBITDA margin.\"\n- Multi-year cash trajectory cited at that conference: free cash flow improved from a $108M outflow in 2023 to near breakeven in 2025 (Investing.com conference coverage, 2026-08-12).\n\n## Bear Case\n- Both post-print sell-side actions landed on the same number: Stifel cut to $13 from $15 with Buy maintained (~2026-08-06) and Canaccord Genuity cut to $13 with Buy maintained (2026-08-10). The 5-analyst average of $21.50 (range $16–$24) displayed on stockanalysis.com as of 2026-08-08 is being marked down toward the tape.\n- Profitability moved backwards on higher sales: Q2 2026 net loss $(15.8)M versus $(14.1)M a year earlier; adjusted EBITDA $20.1M versus $20.6M.\n- Six-month free cash flow $(47.1)M against $(20.6)M in the prior-year period. The 2026-05-21 8-K said the company does not expect positive free cash flow for full-year 2026. Quarter-end cash and equivalents $103.8M against $221.6M of long-term debt. A ~$15M European MDR inventory purchase pushes cash out in 2026 with receipts expected in 2027 (2026-08-12).\n- The smaller-distributor drag was quantified, not resolved: the ~20% of spine revenue outside the top 40 has declined for several quarters and more steeply than management expected (2026-08-12), and the company is selectively deciding which of those partners to keep.\n- No 2027 guidance and no reinstated long-range plan until the U.S. spine business stabilises (2026-08-12). The three-year targets withdrawn on 2026-05-21 stayed withdrawn through a raised FY26 guide.\n- FDA's 2026-04-16 reclassification of non-invasive bone growth stimulators from Class III to Class II lowers the 510(k) barrier into the Therapeutic Solutions franchise, which did $64.2M in Q2 at +2.5%.\n\n## Setup & Price Structure\nThe narrative is **dead**. The narrative got its policy confirmation on 2026-07-02 and its fundamental confirmation on 2026-08-05, and price is lower after both — $10.01 on 2026-08-21 versus $10.28 on 2026-08-07, with a three-month change of -6.9% that places the shares beneath the 2026-05-21 guidance-cut day. A story whose two designed catalysts both fired and left the stock at a lower level has stopped attracting the marginal buyer it needed.\n\nPositioning and crowding observables, stated as observables:\n- RSI(14) at 22.8 on 2026-08-21 — deep oversold. Such readings persist inside downtrends and are not by themselves evidence of a base.\n- Sell-side targets converging downward within five sessions (Stifel $13 on ~2026-08-06, Canaccord $13 on 2026-08-10) while both kept Buy ratings — targets compressing toward price with ratings unchanged.\n- Retail-facing coverage clustered in early July (Benzinga's 2026-07-06 gainer list grouped OFIX with WULF, IREN, CRDO and others) and has gone quiet since; the last 30 days of headlines carry one analyst action and no company release.\n- Insider flow: Form 4 coverage shows director John B. no open-market insider purchase has been reported at the lower August levels through 2026-08-21.\n- No earnings date inside the next 30 days, so there is no scheduled event to force repositioning.\n\nStructure: the $10 handle is the operative reference, intact by a cent-scale margin at the 2026-08-21 close. Below it, the July advance is fully round-tripped with no dated company event until roughly 2026-11-04. Evidence of stabilisation would be weekly closes that stop making lower lows and a reclaim of the 2026-08-07 close of $10.28; that has not occurred in the two weeks between those two closes.\n\n## Catalyst Calendar (next 30 days)\n- 2026-08-22 → 2026-09-21: **no company-dated event.** The last announced appearances were Needham's Virtual MedTech & Diagnostics 1x1 Conference (2026-08-10) and Canaccord Genuity's 46th Annual Growth Conference (2026-08-12); no September conference had been announced as of 2026-08-22.\n- ~2026-10-01 (est.) — CMS quarterly DMEPOS fee-schedule update effective date, with the file posting ahead of it. Tests whether the restored E0747/E0748/E0760 rates carry forward unchanged.\n- ~2026-11-04 (est.) — Q3 2026 results; Q3 2025 was reported 2025-11-04. First full quarter under restored reimbursement.\n- ~2027-02-25 (est.) — Q4/FY2026 results and any FY2027 guide; FY2025 results were released 2026-02-24.\n\n## What Would Change Our Mind\nThe stabilisation case is entirely dependent on the Q3 print supplying three things at once: adjusted EBITDA above the year-ago $20.6M, free cash flow inflecting off the $(47.1)M six-month figure, and revenue landing at or above Q2's $210.9M as the CFO indicated on 2026-08-12. A reinstated long-range plan or an early FY2027 range would signal management's own confidence in the reimbursement base has returned; their continued absence on 2026-11-04 keeps the guide unsupported by anything beyond a single quarter.\n\nOn the tape, a weekly close below $9.80 loses the $10 handle held at the 2026-08-21 close, completing the retrace of the entire July CMS-reversal advance. In the other direction, weekly closes reclaiming the 2026-08-07 level of $10.28 while holding the $10 handle would be the first structural evidence that the distribution since 2026-08-05 is finished.\n\nStructural negatives that would settle the question: a downward revision to HCPCS E0747/E0748/E0760 in a quarterly DMEPOS update, a competitor 510(k) clearance for a non-invasive bone growth stimulator, or any equity/convertible issuance or credit-facility amendment filed against the $221.6M long-term debt.\n\n## Correlation Notes\n- Reimbursement beta dominates: the two largest moves of 2026 (2026-05-21 cut, 2026-07-02 restoration) were CMS-driven and independent of operating results. Other DMEPOS-exposed device names share that factor.\n- U.S. spine peers (Globus Medical, Alphatec and the SeaSpine-lineage names) share the distributor-productivity and hospital-pricing cycle management described on 2026-08-12, including the 1–2% annual price erosion built into projections.\n- Small-cap medtech liquidity: the 2026-07-06 Benzinga list grouped OFIX with unrelated small caps on a single risk-appetite day, which is how the name trades in the absence of company news.\n- FX: the gap between +4% reported and ~5% pro forma constant-currency Q2 growth, plus the euro-denominated MDR inventory build, makes EUR/USD a second-order input to reported revenue and 2026 cash outflow.",
  "first_seen": "2026-07-31",
  "last_analyzed": "2026-08-22T09:46:37+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}